Business
Pharmaceutical Independence Day – Majority of Americans Now Prefer Weed over Prescription Drugs Says New Study
Around 131 million people in the United States take prescription drugs.
That translates to 66% of the population, most of whom belong to the elderly and those who have chronic illnesses. Most adults have one of 5 common chronic conditions that require the use of prescription drugs – these are heart disease, diabetes, cancer, arthritis, and hypertension. Prescription drugs need to be refilled often, so it’s no surprise that the global pharmaceutical industry was worth a staggering 1.42 trillion dollars in 2021.
However, the good news is that more people are seeing the benefits of using cannabis instead.
In a new survey by The Harris Poll and Curaleaf, they found that 91% of American adults aged 21 and up who consume marijuana, do so for health and wellness. They also found that 75% of Americans prefer natural solutions instead of pharmaceutical drugs for treating a condition whenever it’s possible, and 62% of participants said that they prefer to use cannabis as opposed to pharmaceuticals for treating medical problems.
Furthermore, the survey revealed that 88% of people who use cannabis as an alternative or together with pharmaceutical treatments report an improvement in well-being. Meanwhile, 86% of those who have used cannabis would recommend it to their family or friends for treating medical conditions.
“Educating consumers on how cannabis can be leveraged to support everyday health and wellness needs is critical to destigmatizing the plant and providing consumers with more choices to best fit their personal lifestyle,” explains Curaleaf’s Clinical Cannabis Pharmacist, Dr. Stacia Woodcock. “There are a wide variety of ways to consume cannabis safely, and many formulations actually have minimal intoxicating effects. Different product options with various ratios of THC and CBD give patients the opportunity to consume cannabis in a way that works with their lifestyle and comfort level,” she says.
Why People Should Choose Cannabis Over Prescription Drugs
Heart disease, diabetes, arthritis, hypertension, and cancer – these five common chronic conditions can all be treated with medical marijuana, or with marijuana and conventional drugs. There is a growing body of research supporting the safety and efficacy of marijuana for these conditions, and can even help where Big Pharma fails.
Common pharmaceutical drugs that are used to treat these conditions come with undesirable side effects which can even occur when patients take the incorrect dosage, have an allergic reaction to an ingredient used in the medication, when the drugs kill harmful cells AND healthy cells (commonly occurring in the case of chemotherapy), drug interactions with other medications (even supplements and food), and many more. Common side effects include constipation or diarrhea, insomnia, nausea, dizziness, drowsiness, and headaches. However, more dangerous side effects can also occur: internal bleeding, abnormal heart rhythms, cancer, and suicidal thoughts to name a few.
In a study from 2018, researchers analyzed data in the Releaf App, which the study’s authors say is “the largest repository of user-entered information on the consumption and effect of cannabis use in the United States,” it says. There were around 100,000 entries on the site. In one study, they found that users who had one or more of 27 various health problems with different symptoms ranging from depression to seizures reported a reduction of symptoms from 2.6 to 4.6 on a scale of 10, following consumption of medical marijuana.
In another study, researchers found that Releaf App data showed that 94% of marijuana users who were diagnosed with numerous health problems reported that marijuana consumption was effective in reducing the intensity of their symptoms. They also said that marijuana use wasn’t associated with any serious side effects. “If the results found in our studies can be extrapolated to the general population, cannabis could systematically replace multi-billion dollar medication industries around the world. It is likely already beginning to do so,” said the study’s co-author, Jacob Vigil.
In a more recent study, researchers in Canada and Italy analyzed the impact of cannabis use among 214 Canadian patients, most of whom were over 50 years old and who were given authorization by the government to use cannabis products. The researchers analyzed the symptoms of patients as well as quality of life before they took cannabis then 6 weeks after. These patients either had chronic pain, rheumatic disorders, anxiety, sleep disorders, or post-traumatic stress.
All patients who had chronic pain, sleep troubles, arthritis, and post-traumatic stress reported improvements in their symptoms after using cannabis for just 6 weeks. They did however, say that cannabis made them sleepy and gave them a dry mouth.
“Aligning with previously published studies, we report that over 60% of the medical cannabis cohort reported improvements in their medical conditions,” said the authors. “Overall, we have provided new real-world evidence to support the use of medical cannabis in a number of different medical conditions as a means to immediately provide the scientific evidence healthcare practitioners routinely state they require and to inform the future clinical studies needed to generate efficacy and safety data that will ultimately support the drafting of future regulatory guidelines surrounding medical cannabis use,” they concluded.
These are only a few of the many studies available backing up the efficacy of marijuana for a range of health conditions. Patients suffering from nearly any condition can somehow benefit from cannabis use, and there are so many ways you can take it. From smoking to edibles, infused beverages, topicals, patches, and so much more, the possibilities of medicating in a way that benefits you personally is endless. There’s no reason to feel like pharmaceutical drugs is the only choice left if you are struggling with a condition, so talk to your doctor today about integrating cannabis into your treatment.
Business
Alleged Crores Pharma Scam Mastermind Arrested from Surat
After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.
Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.
Fake Business Deals and Dishonoured Cheques Used in Fraud
Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.
In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”
Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.
Multiple Identities and Repeated Fraud Pattern
Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.
Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.
Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.
Multi-State Surveillance Leads to Arrest in Surat
A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.
Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.
Growing Threat of Corporate Identity Fraud
The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.
Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.
Experts Urge Stronger Due Diligence in High-Value Transactions
Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.
Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.
Business
EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices
A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.
Investigation Under Digital Markets Act Gains Momentum
The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.
Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.
Industry Groups Demand Swift Action
Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.
Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.
In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.
Google Denies Allegations
Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.
However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.
Potential Billion-Euro Penalties
If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.
Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.
Wider Implications for Big Tech
The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.
A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.
As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.
AI & Technology
Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations
Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).
The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.
Trial Push Despite Multi-Million Euro Settlement
The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.
Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.
A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.
Allegations of VAT Evasion Through Marketplace Sellers
At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.
Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.
Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.
Italian Government Named as Affected Party
In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.
Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.
Multiple Investigations Add to Pressure
The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.
Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.
In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.
Amazon Denies Allegations
Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.
Broader Impact on Europe’s Digital Economy
If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.
With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
